
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics is receiving support from CSL Behring for the commercialization of KOSTAIVE, a mRNA COVID-19 vaccine, in Asia and Europe. The company's $72/share price target is derived from a risk-adjusted net present value analysis, with a significant portion of the value coming from LUNAR-COVID vaccine global profit share. The delay in US BLA filing for KOSTAIVE has resulted in reduced expenses and an extended runway for ARCT's CF and OTC deficiency programs.
Bears say
Arcturus Therapeutics is facing uncertainty and potential challenges with their ARCT-810 OTC program, as delays and uncertain commercial viability may impact the company's progress. Additionally, the company is still in early stages of clinical trials for their ARCT-032 CF program, with upcoming pivotal studies that will determine the success of the therapy. Given these factors and the company's current cash position, there is a negative outlook on Arcturus Therapeutics' stock.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares